Jump to content
PC Security Forum
FORUMS BLOG/NEWS USER BLOGS USER MEDIA ADVERTS   ADD  MANAGE CHAT CLUBS & USER'S PERSONAL FORUMS LINK EXCHANGE

Mason Joe

  • entries
    13
  • comments
    0
  • views
    64

Presently engaged in evaluating the clinical applications of over 180 cannabinoid-derivatives


Over time, extensive R&D on the potential health benefits of cannabis, have enabled medical researchers to identify a number of pharmacologically active ingredients that offer clinical benefit, minus the addictive properties of the crude substance. Currently, several stakeholders in the pharmaceutical industry are actively engaged in the efforts to develop leads based on natural and synthetic derivatives of cannabinoids.

 

To order this 250+ page report, which features 140+ figures and 170+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

 

The over USD 5 billion (by 2030) financial opportunity within the endocannabinoid system targeted therapeutics market has been analyzed across the following segments:

§  Target Disease Indication

§  Cancer

§  Genetic Disorders

§  Neurological Indications

§  Others

 

§  Route of Administration

§  Oral

§  Inhalation

 

§  Key Geographies

§  North America

§  Europe

Asia-Pacific and the Rest of the World

 

The “Endocannabinoid System Targeted Therapeutics Market, 2020-2030" report features the following companies, which we identified to be key players in this domain:

§  GW Pharmaceuticals

§  Corbus Pharmaceuticals

§  Tilray

§  Tetra Bio-Pharma

§  Botanix Pharmaceuticals

§  Kalytera Therapeutics

§  Therapix Biosciences

§  Echo Pharmaceuticals

§  Avicanna

§  GB Sciences

 

Table of Contents

 

1.         PREFACE

 

2.         EXECUTIVE SUMMARY

 

3.         INTRODUCTION

 

4.         MARKET LANDSCAPE: ENDOCANNABINOID SYSTEM TARGETED THERAPEUTICS

 

5.         COMPANY PROFILES

 

6.         ACADEMIC GRANTS ANALYSIS

 

7.         PARTNERSHIPS AND COLLABORATIONS

 

8.         MERGERS AND ACQUISITIONS

 

9.         DRUG DEVELOPMENT STRATEGY ANALYSIS

10.        MARKET FORECAST AND OPPORTUNITY ANALYSIS

 

11.        CONCLUDING REMARKS

 

12.        EXECUTIVE INSIGHTS

 

13.        APPENDIX 1: TABULATED DATA

 

14.        APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

 

To purchase a copy, please visit https://www.rootsanalysis.com/reports/view_document/endocannabinoid-therapeutics/316.html

 

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Gaurav.Chaudhary@rootsanalysis.com

0 Comments


Recommended Comments

There are no comments to display.

Guest
Add a comment...

×   Pasted as rich text.   Paste as plain text instead

  Only 75 emoji are allowed.

×   Your link has been automatically embedded.   Display as a link instead

×   Your previous content has been restored.   Clear editor

×   You cannot paste images directly. Upload or insert images from URL.

×
  • Create New...